PHILADELPHIA, July 7 — The story of CAR-T cell therapy begins not in a petri dish, but inside the human body, with a patient’s own immune cells. It is a treatment that collects a person’s blood and isolates their T cells through a process called apheresis, which takes two to three hours.
Those cells are then sent to a laboratory, where they are genetically modified using a lentiviral or retroviral vector to express a chimeric antigen receptor, or CAR — a molecular homing device that recognizes a specific antigen on cancer cells. For many patients with B-cell malignancies, that target is CD19.
The modified cells are then expanded in culture for nine to 14 days, producing millions of CAR-T cells ready to be infused back into the patient. Before that infusion, however, the patient receives lymphodepleting chemotherapy — typically cyclophosphamide and fludarabine — for three days. This step reduces the body’s endogenous immune cells, clearing the way for the engineered cells to take hold.
A precision strike against cancer
The actual infusion is intravenous, lasting 30 to 60 minutes. Once inside the body, the CAR-T cells bind to CD19 on the surface of cancer cells. That binding triggers activation, and the CAR-T cells release cytotoxic granules — perforin and granzyme — that kill the target cells.
It is a precision strike, designed to spare healthy tissue while destroying malignancy. The therapy was pioneered by Dr. Carl June at the University of Pennsylvania.
June published the first successful clinical trial results in 2011 in the New England Journal of Medicine, marking a turning point in immunotherapy. That work laid the foundation for what would become the first Food and Drug Administration approval of a CAR-T cell therapy, which came on August 30, 2017, for tisagenlecleucel, marketed as Kymriah, for pediatric acute lymphoblastic leukemia. For families facing a childhood leukemia diagnosis, that FDA approval meant a new option where few had existed before.
The treatment represented not just a scientific milestone, but a tangible shift in what was possible for patients who had run out of conventional therapies.
From the lab bench to the bedside
The journey from June’s laboratory at the University of Pennsylvania to regulatory approval took years of careful clinical work. The 2011 New England Journal of Medicine paper documented the first successful outcomes in patients who had exhausted other treatments. That evidence built the case for the therapy’s potential, and the field has expanded rapidly since.
The mechanism itself is elegant in its design. By engineering the patient’s own T cells to recognize a specific cancer antigen, the therapy essentially turns the immune system into a living drug.
The cells continue to circulate and replicate, providing ongoing surveillance against the cancer. Researchers continue to refine the approach, working to extend it to other cancer types and to reduce side effects. For now, CAR-T cell therapy remains a powerful tool for certain blood cancers, with the promise of further advances on the horizon. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “CAR-T Therapy: Engineering Immune Cells to Fight Cancer”, “description”: “PHILADELPHIA, July 7 — The story of CAR-T cell therapy begins not in a petri dish, but inside the human body, with a patient’s own…”, “datePublished”: “2026-07-07T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “James Roberto”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
